KRAS Status Doesn't Impact Treatment with 5-FU Alone

While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs? 5-FU (fluorouracil) is the backbone of most colorectal cancer… Read More

KRAS Mutation Status Predicts Response to Erbitux in Canadian Study

Another study has shown that colon or rectal cancer patients whose tumors have mutated KRAS don’t benefit from Erbitux® (cetuximab). However, in the study when only patients with normal or wild-type KRAS were considered, survival time almost doubled after treatment… Read More